{"id":19366,"date":"2026-05-07T22:06:02","date_gmt":"2026-05-07T20:06:02","guid":{"rendered":"https:\/\/www.ngdcare.nl\/gan-catagoir\/shilait\/"},"modified":"2026-05-07T22:06:02","modified_gmt":"2026-05-07T20:06:02","slug":"shilait","status":"publish","type":"post","link":"https:\/\/www.ngdcare.nl\/ga\/blag\/shilait\/","title":{"rendered":"Shilait"},"content":{"rendered":"
\n
NGD Care \u2014 C\u00falra eola\u00edoch d’fhorl\u00edonta\u00ed bia<\/div>\n

Shilajit:
\n aig\u00e9ad fulvic, mitochondria agus neuroprotection m\u00ednithe<\/span><\/h1>\n

D\u00e9anta ar feadh na m\u00edlte bliain sna sl\u00e9ibhte arda \u00f3 dh\u00edle\u00e1 \u00e1bhar planda\u00ed agus anois staid\u00e9ar mar cheann de na comhdh\u00faile bithghn\u00edomhacha is casta i bhforl\u00edonadh. Forbhreathn\u00fa domhain ar an bhfiseola\u00edocht, na comhph\u00e1irteanna gn\u00edomhacha agus an bun\u00fas eola\u00edoch. Do dhaoine, madra\u00ed agus cait. <\/p>\n

De r\u00e9ir Stefan Veenstra DVM<\/p>\n<\/div>\n

\n

Cad \u00e9 shilajit: phytocomplex, n\u00ed forl\u00edonadh<\/h2>\n

N\u00ed substaint amh\u00e1in \u00e9 Shilajit ach phytocomplex: maitr\u00eds saibhir \u00f3 thaobh na bitheola\u00edochta de na c\u00e9adta comhdh\u00faile a chrutha\u00edtear tr\u00ed thiont\u00fa \u00e1bhar planda\u00ed na m\u00edlte bliain ag miocrorg\u00e1naigh faoi bhr\u00fa ard agus teocht i scoilteanna carraige arda sl\u00e9ibhe. Athra\u00edonn a chomhdh\u00e9anamh de r\u00e9ir bun\u00fas geografach, ach l\u00e9ir\u00edonn a phr\u00f3if\u00edl bhithghn\u00edomhach tr\u00e9ithe comhsheasmhacha: aig\u00e9ad fulvic, aig\u00e9ad humach, dibenzo-alfa-pyrones (DBPanna), mianra\u00ed i bhfoirm ianach agus polyphenols. [1]<\/a><\/sup><\/p>\n

I leigheas Ayurvedic, t\u00e1 cur s\u00edos d\u00e9anta ar shilajit le breis agus 3000 bliain mar rasayana, tonic athnuachana d\u00edrithe ar bheocht agus ar bheocht. Sol\u00e1thra\u00edonn anail\u00eds ch\u00f3gaseola\u00edoch nua-aimseartha m\u00edni\u00fa bitheola\u00edoch inchreidte ar an gc\u00e1il thraidisi\u00fanta seo, agus is \u00e9 aig\u00e9ad fulvic an cod\u00e1n gn\u00edomhach is m\u00f3 a ndearnadh staid\u00e9ar air. <\/p>\n

N\u00ed forl\u00edonadh amh\u00e1in \u00e9 Shilajit ach phytocomplex de na c\u00e9adta comhdh\u00faile bithghn\u00edomhacha. T\u00e1 an \u00e9ifeacht leathan agus ilchisealach: ag an am c\u00e9anna frithocsa\u00eddeach, iompr\u00f3ir mianra\u00ed, frith-athlastach agus taca\u00edocht mitochondrial. <\/div>\n
Shilajit i bPr\u00f3tacail<\/strong>
\n Ch\u00faraim NGDPr\u00f3tacal Gut C\u00faraim NGD: shilajit mar chomhph\u00e1irt ch\u00e9im 2 do dhaoine<\/a>
\nPr\u00f3tacal Aos\u00fa C\u00faraim NGD: Taca\u00edocht Mitochondrial agus Inflammaging-Inhibition<\/a>
\nPr\u00f3tacal Comhph\u00e1irteach C\u00faraim NGD: Taca\u00edocht Frith-Athlastach agus Collagen<\/a><\/div>\n

Aig\u00e9ad fulvic: cro\u00ed gn\u00edomhach shilajit<\/h2>\n

Is gn\u00e1ch gurb ionann aig\u00e9ad fulvic agus 60 go 80% den east\u00f3scadh me\u00e1chain tirim de shilajit ardchaighde\u00e1in. Is polaileictril\u00edt \u00e9 le me\u00e1chan m\u00f3il\u00edneach thar a bheith \u00edseal de thart ar 2 kDa, rud a ligeann d\u00f3 seicn\u00ed bitheola\u00edocha a thre\u00e1 gan str\u00f3. [1]<\/a><\/sup><\/p>\n

\n
\n
Frithocsa\u00eddeoir<\/div>\n

Neodra\u00edonn anions superoxide agus fr\u00e9amhacha hiodrocsaile tr\u00ed chumas deonaithe leictreon. Gn\u00edomha\u00edocht frithocsa\u00eddeach speictrim leathan a chuireann teorainn dh\u00edreach le dam\u00e1iste cille ocsa\u00eddi\u00fach\u00e1in. [2]<\/a><\/sup><\/p>\n<\/div>\n

\n
Iompr\u00f3ir mianra\u00ed<\/div>\n

Foirm\u00edonn s\u00e9 coimpl\u00e9isc le hiain mianra\u00ed d\u00e9fhi\u00fasacha agus tr\u00edfhi\u00fasacha (iarann, since, maign\u00e9isiam, mangain\u00e9is) le haghaidh iompair ghn\u00edomhach thar an epithelium intestinal. M\u00e9ada\u00edonn s\u00e9 go suntasach bith-infhaighteacht mianra\u00ed. [3]<\/a><\/sup><\/p>\n<\/div>\n

\n
Inhibitor NF-kB<\/div>\n

Cuireann s\u00e9 cosc ar an bhfacht\u00f3ir trascr\u00edobh l\u00e1rnach de th\u00e1irgeadh cytokine pro-inflammatory (TNF-alfa, IL-1 beta, IL-6). Ag an am c\u00e9anna, activator an chonair Nrf2 \/ HO-1 le haghaidh eins\u00edm\u00ed frithocsa\u00eddeacha endogenous. [4]<\/a><\/sup><\/p>\n<\/div>\n

\n
Spreagth\u00f3ir Akkermansia<\/div>\n

Spreagann s\u00e9 go roghnach Akkermansia muciniphila, an pr\u00edomhspeiceas le haghaidh t\u00f3g\u00e1il ciseal mucus agus l\u00e9iri\u00fa acomhal daingean sa bhalla intestinal. Rannchuidi\u00fa d\u00edreach le deisi\u00fa bacainn intestinal. [10]<\/a><\/sup><\/p>\n<\/div>\n<\/div>\n

Dibenzo-alfa-pyrones agus t\u00e1irgeadh fuinnimh mitochondrial<\/h2>\n

Chomh maith le haig\u00e9ad fulvic, t\u00e1 gr\u00fapa comhdh\u00faile uath\u00fala i shilajit nach bhfuil le f\u00e1il in aon bhia n\u00f3 forl\u00edonadh eile: dibenzo-alfa-pyrones (DBPanna). Idirghn\u00edomha\u00edonn na comhdh\u00faile seo go d\u00edreach leis an slabhra iompair leictreon sna mitochondria agus oibr\u00edonn siad go sineirgisteach le coenzyme Q10<\/a>. <\/p>\n

Taca\u00edonn DBPanna le meitibileacht fuinnimh mitochondrial tr\u00ed dh\u00e1 mheicn\u00edocht: tr\u00ed leictreoin a threor\u00fa chuig casta I agus II den slabhra iompair, agus tr\u00ed chobhsa\u00edocht ubiquinone a mh\u00e9ad\u00fa agus a athghabh\u00e1il sa slabhra a chur chun cinn. In \u00e9ineacht le forl\u00edonadh CoQ10, feabhsa\u00edonn shilajit t\u00e1irgeadh ATP ag an leibh\u00e9al ceallach, maoin at\u00e1 \u00e1bhartha go clinici\u00fail i dtuirse, seanaois, agus coinn\u00edollacha degenerative. [5]<\/a><\/sup><\/p>\n

\n

Staid\u00e9ar clinici\u00fail \u00b7 2012 \u00b7 Taca\u00edocht chogna\u00edoch agus galar Alzheimer<\/p>\n

D’aithin Carrasco-Gallardo et al. aig\u00e9ad fulvic mar mh\u00f3il\u00edn frith-Alzheimer f\u00e9ideartha bunaithe ar a chumas cosc a chur in vitro ar chomhioml\u00e1n\u00fa pr\u00f3it\u00e9ine tau, ceann den d\u00e1 ghn\u00e9 phaiteola\u00edocha de Alzheimer chomh maith le amyloid-beta. Chuir na taighdeoir\u00ed s\u00edos ar aig\u00e9ad fulvic mar fhacht\u00f3ir a chuireann i gcoinne hyperphosphorylation tau agus a chuireann isteach ar fhoirmi\u00fa tangles neurofibrillary. [6]<\/a><\/sup><\/p>\n<\/div>\n

\n

L\u00e9irmheas \u00b7 IJBCP 2025 \u00b7 Modhn\u00fa NF-kB agus Nrf2<\/p>\n

Dheimhnigh Gupta et al. i staid\u00e9ar athbhreithnithe le d\u00e9ana\u00ed go mb\u00edonn \u00e9ifeachta\u00ed frithocsa\u00eddeacha agus frith-athlastacha cumhachtacha ag shilajit tr\u00ed mhodhn\u00fa comhordaithe NF-kB (cosc) agus Nrf2 \/ HO-1 (gn\u00edomhacht\u00fa). Deimhn\u00edodh aig\u00e9ad fulvic mar an pr\u00edomhchod\u00e1n gn\u00edomhach, chomh maith le rannchuidi\u00fa DBPanna le feidhm mitochondrial. [4]<\/a><\/sup><\/p>\n<\/div>\n

Cneasaithe cn\u00e1mh, collagen agus f\u00edoch\u00e1n nascach<\/h2>\n

Spreagann Shilajit l\u00e9iri\u00fa marc\u00f3ir\u00ed osteoblast agus luasgh\u00e9ara\u00edonn s\u00e9 mianr\u00fa maitr\u00eds cn\u00e1mh i samhlacha in-vitro agus in-vivo. Luasgh\u00e9ara\u00edonn Shilajit pr\u00f3isis cneasaithe cn\u00e1mh tr\u00ed bheala\u00ed iolracha: gn\u00edomha\u00edocht fosfat\u00e1ise alcaileach a spreagadh, sint\u00e9is m\u00e9adaithe collagen cine\u00e1l I, agus gn\u00edomha\u00edocht osteoclast a chur faoi chois. [7]<\/a><\/sup><\/p>\n

\n

CCI \u00b7 J Sol\u00e1thar aiste bia 2024 \u00b7 Sint\u00e9is collagen cine\u00e1l I<\/p>\n

L\u00e9irigh Neltner et al. i dtriail rialaithe randamach gur mh\u00e9adaigh ocht seachtaine d’fhorl\u00edonadh shilajit leibh\u00e9il serum Pro-c1alfa1 go suntasach, bithmharc\u00f3ir sonrach do shint\u00e9is collagen cine\u00e1l 1, i gcoibhneas le phlaic\u00e9ab\u00f3. T\u00e1 impleachta\u00ed d\u00edreacha aige seo do shl\u00e1inte craicinn, cn\u00e1mh agus cartilage i ndaoine agus in ainmhithe araon. [8]<\/a><\/sup><\/p>\n<\/div>\n

\u00c1bharthacht do mhadra\u00ed agus do chait<\/h2>\n

N\u00edl meicn\u00edochta\u00ed bithghn\u00edomhacha shilajit speiceas-shonrach. Is pr\u00f3isis bhitheola\u00edocha bhun\u00fasacha iad an cos\u00e1n NF-kB, slabhra iompair leictreon mitochondrial, agus comhioml\u00e1n\u00fa pr\u00f3it\u00e9ine tau a fheidhm\u00edonn go comhionann i ngach mamaigh. Sa chomhth\u00e9acs tr\u00e9idliachta, rinneadh staid\u00e9ar ar shilajit i madra\u00ed le airtr\u00edteas measartha: l\u00e9irigh staid\u00e9ar inar fuair c\u00faig mhadra 500 mg de shilajit ar feadh 120 l\u00e1 laghduithe suntasacha ar phian agus bithmharc\u00f3ir\u00ed athlastacha tar \u00e9is 60 l\u00e1 i gcompar\u00e1id leis an ngr\u00fapa phlaic\u00e9ab\u00f3, gan aon chomhartha\u00ed fadhbanna caoinfhulaingt. [9]<\/a><\/sup><\/p>\n

I madra\u00ed agus cait n\u00edos sine, t\u00e1 an teaglaim de thaca\u00edocht mitochondrial tr\u00ed DBPanna, gn\u00edomh frith-athlastach tr\u00ed aig\u00e9ad fulvic agus sol\u00e1thar mianra\u00ed \u00e1bhartha go h\u00e1irithe. T\u00e1 baint ag dul in aois i feoiliteoir\u00ed leis na sainmharcanna c\u00e9anna agus at\u00e1 i ndaoine: m\u00edfheidhm mitochondrial, athlastadh, agus caillteanas proteostasis. Tugann Shilajit aghaidh ar roinnt de na beala\u00ed seo ag an am c\u00e9anna. <\/p>\n

Idirghn\u00edomha\u00edochta\u00ed, fo-iarsma\u00ed agus contraindications<\/h2>\n
C\u00e1il\u00edocht agus \u00edonacht: pointe critici\u00fail<\/strong><\/p>\n

D’fh\u00e9adfadh miotail throma, lena n-\u00e1ir\u00edtear luaidhe, mearcair, arsanaic agus caidmiam a bheith i shilajit neamhghlan n\u00f3 pr\u00f3ise\u00e1ilte go neamhleor. N\u00e1 h\u00fas\u00e1id ach t\u00e1irg\u00ed at\u00e1 t\u00e1st\u00e1ilte le haghaidh miotail throma ag tr\u00ed\u00fa p\u00e1irt\u00ed agus caighde\u00e1naithe le haghaidh cion aig\u00e9ad fulvic (60% ar a laghad). N\u00ed crit\u00e9ar marga\u00edochta \u00e9 seo ag shilajit ach riachtanas s\u00e1bh\u00e1ilteachta. <\/p>\n<\/div>\n

\n
Fo-iarsma\u00ed<\/strong>
\n f\u00e9idearthaAg d\u00e1ileoga arda, gear\u00e1in gastrointestinal \u00e9adroma (nausea, st\u00f3il bhog). Frithghn\u00edomhartha craicinn aill\u00e9irgeacha neamhchoitianta. Leibh\u00e9il urate ardaithe is f\u00e9idir i ndaoine braiche-seans maith mar gheall ar \u00e1bhar purine. M\u00e9ad\u00fa sealadach ar pharaim\u00e9adair iarainn tr\u00ed ghn\u00edomh iompair mianra\u00ed. <\/div>\n
Contraindications<\/strong>
\nNeamhdh\u00f3thanacht du\u00e1nach: m\u00e9ada\u00edonn shilajit ions\u00fa mianra\u00ed agus d’fh\u00e9adfadh br\u00fa du\u00e1nach a mh\u00e9ad\u00fa. Gout n\u00f3 hyperuricemia: rabhadh mar gheall ar \u00e1bhar purine. Ionfhabhtuithe gn\u00edomhacha le fiabhras: d’fh\u00e9adfadh spreagadh gn\u00edomha\u00edochta imdh\u00edonachta a bheith neamh-inmhianaithe i gc\u00e1s fiabhras ard. Galair r\u00f3-ualach iarainn (hemochromatosis): is riosca \u00e9 ions\u00fa iarainn m\u00e9adaithe ansin. <\/div>\n<\/div>\n
\n
Idirghn\u00edomha\u00edochta\u00ed le c\u00f3gais<\/strong>
\nTanaithe fola (warfarin, heparin): t\u00e1 air\u00edonna frith-t\u00e9achtacha beaga ag aig\u00e9ad fulvic, \u00e9il\u00edonn an teaglaim monat\u00f3ireacht a dh\u00e9anamh. Forl\u00edonadh iarainn: n\u00e1 h\u00fas\u00e1id ag an am c\u00e9anna mar gheall ar r\u00f3-spreagadh ions\u00fa iarainn. C\u00f3gais antidiabetic: laghda\u00edonn shilajit si\u00facra fola, nuair a \u00fas\u00e1idtear \u00e9 ag an am c\u00e9anna a choigeart\u00fa dosage insulin n\u00f3 metformin. <\/div>\n
\n S\u00e1bh\u00e1ilteacht ainmhithe<\/strong>Rinneadh staid\u00e9ar ar Shilajit mar fhorl\u00edonadh i madra\u00ed gan aon fhionnachtana tocsaineola\u00edocha ag gn\u00e1thdh\u00e1ileoga\u00ed. I gcait, t\u00e1 an fhianaise teoranta: ba ch\u00f3ir a bheith c\u00faramach ag d\u00e1ileoga os cionn an raon molta. T\u00e9igh i gcomhairle le tr\u00e9idlia i gc\u00f3na\u00ed nuair a \u00fas\u00e1ideann t\u00fa \u00e9 ar ainmhithe breoite n\u00f3 \u00edocleasaithe. <\/div>\n<\/div>\n

Sineirg\u00edocht le forl\u00edonta\u00ed agus pr\u00f3tacail eile<\/h2>\n

Cuid de Phr\u00f3tacal Bput\u00f3g C\u00faraim NGD: c\u00e9im 2 (do dhaoine)<\/h3>\n

Is comhph\u00e1irt l\u00e1rnach de Ch\u00e9im 2 de Phr\u00f3tacal Bput\u00f3g C\u00faraim NGD (Seachtain\u00ed 8 go 16) \u00e9 Shilajit, tr\u00edna chomhph\u00e1irt aig\u00e9ad fulvic, do dhaoine. Tar \u00e9is d\u00edghr\u00e1d\u00fa bithscann\u00e1in agus cosc athlasadh i gc\u00e9im 1, t\u00e1 an gut r\u00e9idh le haghaidh feidhm bhacainn agus t\u00f3g\u00e1il microbiome a athbhun\u00fa. T\u00e1 r\u00f3l ag Shilajit anseo ar thr\u00ed leibh\u00e9al: spreagadh Akkermansia muciniphila le haghaidh ciseal mucus agus acomhail daingean, seachadadh mianra\u00ed mar chomhfhacht\u00f3ir\u00ed do phr\u00f3isis deisi\u00fach\u00e1in intestinal, agus taca\u00edocht fuinnimh mitochondrial do na enterocytes at\u00e1 ag roinnt go tapa. Maidir le hainmhithe, is \u00e9 Taca\u00edocht Bacainn Gut (aig\u00e9id fulvic agus humic) an rogha cu\u00ed i gc\u00e9im 2. Mar sin f\u00e9in, is f\u00e9idir an shijajit a chur in ionad \u00e9 seo m\u00e1s mian leis an teiripeoir \u00e9. <\/p>\n

Sineirg\u00edocht le L-Glutamine<\/h3>\n

Sol\u00e1thra\u00edonn L-Glutamine an fhoinse n\u00edtrigine dh\u00edreach agus an breosla le haghaidh iomad\u00fa enterocyte agus t\u00e1irgeadh pr\u00f3it\u00e9ine acomhal daingean. D\u00e9anann Shilajit an timpeallacht meitibileach a bharrfheabhs\u00fa: seachadadh mianra\u00ed n\u00edos fearr, taca\u00edocht mitochondrial agus spreagadh Akkermansia. Gn\u00edomha\u00edonn an d\u00e1 shubstaint ar an gcusp\u00f3ir c\u00e9anna, deisi\u00fa bacainn gut, tr\u00ed phoint\u00ed iontr\u00e1la bithcheimiceacha go hioml\u00e1n difri\u00fail, rud a fh\u00e1gann go bhfuil an breise\u00e1n teaglaim ann. <\/p>\n

Sineirg\u00edocht le Ubiquinone Liposomal (CoQ10)<\/h3>\n

T\u00e1 an comhoibri\u00fa idir shilajit agus coenzyme Q10 ar cheann de na hidirghn\u00edomha\u00edochta\u00ed forl\u00edonta is fearr a thaca\u00edtear leo i leigheas mitochondrial. D\u00e9anann DBPanna \u00f3 shilajit ubiquinone a chobhs\u00fa agus a athghabh\u00e1il isteach sa slabhra iompair leictreon mitochondrial a chur chun cinn. Sa Phr\u00f3tacal Seanaoise agus i gc\u00e9im 3 den phr\u00f3tacal gut, \u00fas\u00e1idtear shilajit agus Liposomal Ubiquinone mar ph\u00e9ir\u00ed sineirgisteacha. [5]<\/a><\/sup><\/p>\n

\n

R\u00e9imse iarratais Shilajit<\/h3>\n

Deisi\u00fach\u00e1n bacainn intestinal i gc\u00e9im 2 den Phr\u00f3tacal Intestinal C\u00faram NGD. Taca\u00edocht mitochondrial i tuirse agus seanaois. Inflammaging-inhibition agus athlasadh ainsealach \u00edseal-ghr\u00e1d. Taca\u00edocht chogna\u00edoch le haghaidh dul in aois. Collagen agus t\u00f3g\u00e1il cn\u00e1mh. Taca\u00edocht chomhph\u00e1irteach i dteannta an Phr\u00f3tacail Chomhph\u00e1irtigh. Pr\u00f3tacal ag dul in aois do chomhph\u00e1irt fuinnimh mitochondrial. <\/p>\n<\/div>\n

\n

Concl\u00faid<\/h2>\n

Is phytocomplex \u00e9 Shilajit le pr\u00f3if\u00edl gn\u00edomha\u00edochta uath\u00fail agus ilchisealach: aig\u00e9ad fulvic mar frithocsa\u00eddeoir, iompr\u00f3ir mianra\u00ed, inhibitor NF-kB agus spreagth\u00f3ir Akkermansia, agus DBPanna mar thaca\u00edocht fuinnimh mitochondrial i sineirg\u00edocht le CoQ10. Tugann an teaglaim aghaidh ag an am c\u00e9anna ar dheisi\u00fa bacainn gut, athlasadh ainsealach, meath mitochondrial, agus dul in aois chogna\u00edoch. <\/p>\n

T\u00e1 rial\u00fa c\u00e1il\u00edochta riachtanach: n\u00ed h\u00fas\u00e1id ach shilajit caighde\u00e1naithe agus t\u00e1st\u00e1ilte tr\u00ed\u00fa p\u00e1irt\u00ed. T\u00e1 na caighde\u00e1in ch\u00e1il\u00edochta is airde ag shilajit NGD Care agus t\u00e1 tuarasc\u00e1lacha t\u00e1st\u00e1la ar f\u00e1il i gc\u00f3na\u00ed. T\u00e9igh i gcomhairle le docht\u00fair n\u00f3 tr\u00e9idlia i gc\u00f3na\u00ed i gc\u00e1s \u00fas\u00e1id chomhthr\u00e1thach tanaithe fola, druga\u00ed antidiabetic n\u00f3 neamhdh\u00f3thanacht du\u00e1nach. <\/p>\n<\/div>\n

\n

F\u00e9ach ar Shilajit sa siopa gr\u00e9as\u00e1in NGD Care<\/p>\n

Chuig leathanach an t\u00e1irge<\/a><\/p>\n<\/div>\n

\n

Litr\u00edocht<\/h2>\n
    \n
  1. Carrasco-Gallardo C, Guzm\u00e1n L, Maccioni RB. Shilajit: phytocomplex n\u00e1d\u00fartha le gn\u00edomha\u00edocht procognitive f\u00e9ideartha. Int J Alzheimers Dis.<\/em> 2012;2012:674142. <\/li>\n
  2. Winkler J, Ghosh S. Poit\u00e9inseal teiripeach aig\u00e9ad fulvic i ngalair athlastacha ainsealacha agus diaib\u00e9iteas. J Diaib\u00e9iteas Res.<\/em> 2018;2018:5391014.<\/li>\n
  3. Schepetkin IA, Xie G, Jutila MA, Quinn MT. Gn\u00edomha\u00edocht chomhl\u00e1ntaithe-shocraithe aig\u00e9ad fulvic \u00f3 Shilajit agus foins\u00ed n\u00e1d\u00fartha eile. Phytother Res.<\/em> 2009; 23(3):373\u2013384. <\/li>\n
  4. Gupta V, Keshari B, Tiwari S, et al. Staid\u00e9ir chlinici\u00fala agus fianaise s\u00e1bh\u00e1ilteachta maidir le tomhaltas an duine de Shilajit. Int J Bun\u00fasach Clin Pharmacol.<\/em> 2025. doi (ar l\u00edne ar dt\u00fas).<\/li>\n
  5. Bhattacharyya S, Pal D, Gupta AK, et al. \u00c9ifeacht tairbhi\u00fail Shilajit pr\u00f3ise\u00e1ilte ar chleachtadh sn\u00e1mha spreag st\u00e1das fuinnimh lagaithe lucha. C\u00f3gaseola\u00edocht ar l\u00edne.<\/em> 2009; 1:817\u2013825.<\/li>\n
  6. Carrasco-Gallardo C, et al. Aig\u00e9ad fulvic mar inhibitor ar chomhioml\u00e1n\u00fa pr\u00f3it\u00e9ine tau. Int J Alzheimers Dis.<\/em> 2012;2012:674142. <\/li>\n
  7. Pawar V, et al. Shilajit agus cneasaithe cn\u00e1mh: athbhreithni\u00fa ar ghn\u00edomha\u00edocht bhitheola\u00edoch. 2022.<\/li>\n
  8. Neltner TJ, Sahoo PK, Smith RW, et al. \u00c9ifeachta\u00ed 8 seachtaine d’fhorl\u00edonadh shilajit ar serum Pro-c1alfa1, bithmharc\u00f3ir de shint\u00e9is collagen cine\u00e1l 1: triail rialaithe randamach. J Sol\u00e1thar aiste bia.<\/em> 2024; 21:1\u201312.<\/li>\n
  9. Breathn\u00f3ireacht chlinici\u00fail: staid\u00e9ar shilajit 500 mg 120 l\u00e1 i madra\u00ed airtr\u00edteach. Purblack.com (2021). <\/li>\n
  10. Plovier H, Everard A, Druart C, et al. Feabhsa\u00edonn pr\u00f3it\u00e9in membrane \u00edonaithe \u00f3 Akkermansia muciniphila meitibileacht i lucha murtallach agus diaib\u00e9iteas. Nat Med.<\/em> 2017; 23(1):107\u2013113. <\/li>\n<\/ol>\n<\/div>\n

    T\u00e1 an t-eolas seo oideachas\u00fail \u00f3 thaobh n\u00e1d\u00fair de agus bunaithe ar an litr\u00edocht eola\u00edoch at\u00e1 ar f\u00e1il. N\u00ed bh\u00edonn na staid\u00e9ir a luaitear i gc\u00f3na\u00ed go d\u00edreach tr\u00e9idliachta n\u00f3 sonrach don fhoirmli\u00fa a thuairisc\u00edtear anseo. N\u00ed thagann an t\u00e9acs seo in ionad comhairli\u00fach\u00e1n tr\u00e9idliachta agus n\u00edl aon \u00e9ilimh theiripeacha ann. <\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    NGD Care \u2014 C\u00falra eola\u00edoch d’fhorl\u00edonta\u00ed bia Shilajit: aig\u00e9ad fulvic, mitochondria agus neuroprotection m\u00ednithe D\u00e9anta ar feadh na m\u00edlte bliain sna sl\u00e9ibhte arda \u00f3 dh\u00edle\u00e1 \u00e1bhar planda\u00ed agus anois staid\u00e9ar mar cheann de na comhdh\u00faile bithghn\u00edomhacha is casta i bhforl\u00edonadh. Forbhreathn\u00fa domhain ar an bhfiseola\u00edocht, na comhph\u00e1irteanna gn\u00edomhacha agus an bun\u00fas eola\u00edoch. Do dhaoine, madra\u00ed … Read more<\/a><\/p>\n","protected":false},"author":2,"featured_media":19377,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wds_primary_category":0,"footnotes":""},"categories":[1788,8504],"tags":[],"class_list":["post-19366","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blag","category-forliontai-a-dhoimhniu-eolaioch","infinite-scroll-item"],"_links":{"self":[{"href":"https:\/\/www.ngdcare.nl\/ga\/wp-json\/wp\/v2\/posts\/19366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ngdcare.nl\/ga\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ngdcare.nl\/ga\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ngdcare.nl\/ga\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ngdcare.nl\/ga\/wp-json\/wp\/v2\/comments?post=19366"}],"version-history":[{"count":0,"href":"https:\/\/www.ngdcare.nl\/ga\/wp-json\/wp\/v2\/posts\/19366\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ngdcare.nl\/ga\/wp-json\/wp\/v2\/media\/19377"}],"wp:attachment":[{"href":"https:\/\/www.ngdcare.nl\/ga\/wp-json\/wp\/v2\/media?parent=19366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ngdcare.nl\/ga\/wp-json\/wp\/v2\/categories?post=19366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ngdcare.nl\/ga\/wp-json\/wp\/v2\/tags?post=19366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}